Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Solventum Corporation

SOLV

In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and infection prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.

Last trade $87.00
Day change -$1.65 (-1.86%)
Day range $74.45 – $88.88
Volume 313,779
Market cap $15.05B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$15.05B
Price / earnings
96.46×
Price / book
3.13×
Price / sales
1.84×
EV / sales
2.43×
EV / EBITDA
-34.62×

Profitability

Earnings per share
$0.92
Return on assets
1.1%
Return on equity
3.25%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.1×
Current ratio
1.03×
Quick ratio
0.72×
Cash ratio
0.13×

Cash flow

Price / cash flow
48.54×
Price / free cash flow
—
Free cash flow
$0

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SOLV, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.95B$2.21B$2.01B$2B$2.1B$2.16B$2.07B$2.08B
Cost of revenue$887M$923M$910M$971M$961M$986M$956M$956M
Gross profit$1.06B$1.29B$1.1B$1.03B$1.14B$1.18B$1.11B$1.12B
Selling, general and administrative$813M$927M$827M$759M$780M$772M$769M$784M
Research and development$181M$178M$189M$175M$183M$189M$193M$199M
Total operating expenses$994M$1.11B$1.02B$2.45B$963M$961M$962M$983M
Operating income$68M$181M$81M-$1.43B$172M$214M$152M$136M
Interest expense-$68M-$64M-$62M$0-$89M-$103M-$104M$0
Income before taxes-$11M$108M$16M$58M$1.51B$103M$38M$13M
Income taxes$1M$15M$3M-$5M$248M$13M-$99M-$17M
Net income-$12M$93M$13M$63M$1.27B$90M$137M$30M
Net income attributable to common shareholders-$12M$92M$13M$63M$1.27B$90M$137M$31M
EBITDA$204M$314M$216M-$1.31B$293M$336M$281M$286M
Basic earnings per share-$0.07$0.53$0.07$0.36$7.26$0.52$0.79$0.18
Diluted earnings per share-$0.07$0.53$0.07$0.36$7.22$0.51$0.78$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Solventum (SOLV) is a Top-Ranked Momentum Stock: Should You Buy?

Solventum Corporation (SOLV), a healthcare company spun off from 3M, has received a #2 (Buy) rating on the Zacks Rank with a B VGM Score. The stock has shown positive momentum with a 1.6% gain over four weeks, and five analysts have revised earnings estimates upward for fiscal 2026, increasing the consensus estimate to $7.29 per share.

Zacks Investment Research

Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Solventum reported Q3 2026 revenue of $1.95 billion, down 7% year-over-year, slightly missing the $1.97 billion consensus estimate. However, EPS of $1.45 beat expectations with a +7.41% surprise versus the $1.35 estimate. The company showed mixed performance across segments, with MedSurg and Health Information Systems posting modest gains, while Dental Solutions declined 6.8%. The stock has a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Solventum (SOLV) Tops Q3 Earnings Estimates

Solventum reported Q3 2026 earnings of $1.45 per share, beating consensus estimates of $1.35 by 7.41%, but revenues of $1.95 billion missed expectations by 1.07%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Services industry ranks in the top 45% of Zacks industries.

Zacks Investment Research

Here's Why You Should Hold Solventum Stock in Your Portfolio for Now

Solventum (SOLV) is well-positioned for growth with strong Q2 2026 performance, a $500M cost-saving transformation program, and 18% projected earnings growth for 2026. However, the company faces potential margin headwinds from a 3M supply agreement that could increase raw material costs by up to 100 basis points in 2027.

Zacks Investment Research

SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?

Solventum (SOLV) is set to report Q3 2026 earnings on Nov. 5 with projected 8% earnings decline and 6% revenue decline. While MedSurg and Dental segments show strong momentum and Acera demonstrates 48% Q2 growth, the company faces headwinds from a $125M ERP-related order reversal, tariff pressures, and margin compression. Despite challenges, Zacks' model predicts an earnings beat with a +10.15% Earnings ESP and Rank #3 rating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.